<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pain Rep</journal-id><journal-id journal-id-type="iso-abbrev">Pain Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3291</journal-id><journal-id journal-id-type="pmc-domain">painreps</journal-id><journal-id journal-id-type="publisher-id">Painreports</journal-id><journal-title-group><journal-title>Pain Reports</journal-title></journal-title-group><issn pub-type="epub">2471-2531</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10789452</article-id><article-id pub-id-type="pmcid-ver">PMC10789452.1</article-id><article-id pub-id-type="pmcaid">10789452</article-id><article-id pub-id-type="pmcaiid">10789452</article-id><article-id pub-id-type="pmid">38226027</article-id><article-id pub-id-type="doi">10.1097/PR9.0000000000001080</article-id><article-id pub-id-type="publisher-id">PAINREPORTS-D-22-0128</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>5</subject></subj-group><subj-group subj-group-type="heading"><subject>Musculoskeletal</subject><subj-group><subject>Research Paper</subject></subj-group></subj-group></article-categories><title-group><article-title>Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2087-3349</contrib-id><name name-style="western"><surname>Bested</surname><given-names initials="K">Kirsten</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jensen</surname><given-names initials="LM">Lotte M.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><email>Lotte.Marie.Jensen@rsyd.dk</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Andresen</surname><given-names initials="T">Trine</given-names></name><xref rid="aff2" ref-type="aff">b</xref><email>Trine.Andresen2@rsyd.dk</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tarp</surname><given-names initials="G">Grete</given-names></name><xref rid="aff1" ref-type="aff">a</xref><email>Grete.Tarp@rsyd.dk</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Skovbjerg</surname><given-names initials="L">Louise</given-names></name><xref rid="aff3" ref-type="aff">c</xref><email>louiseskovbjerg@gmail.com</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Johansen</surname><given-names initials="TSD">Torben S.D.</given-names></name><xref rid="aff4" ref-type="aff">d</xref><email>torben.skov.johansen@gmail.com</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schmedes</surname><given-names initials="AV">Anne V.</given-names></name><xref rid="aff5" ref-type="aff">e</xref><email>Anne.Vibeke.Schmedes@rsyd.dk</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Storgaard</surname><given-names initials="IK">Ida K.</given-names></name><xref rid="aff6" ref-type="aff">f</xref><email>ida.storgaard@sund.ku.dk</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Madsen</surname><given-names initials="JS">Jonna S.</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff7" ref-type="aff">g</xref><email>Jonna.Skov.Madsen@rsyd.dk</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Werner</surname><given-names initials="MU">Mads U.</given-names></name><xref rid="aff3" ref-type="aff">c</xref><email>mads.u.werner@gmail.com</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bendiksen</surname><given-names initials="A">Anette</given-names></name><xref rid="aff1" ref-type="aff">a</xref><email>a.bendiksen@hotmail.com</email></contrib><aff id="aff1"><label>a</label>Multidisciplinary Pain Clinic, Friklinikken, Grindsted, <country>Denmark</country></aff><aff id="aff2"><label>b</label>Molecular Diagnostics and Clinical Research Unit, Hospital Sonderjylland, Aabendraa, <country>Denmark</country></aff><aff id="aff3"><label>c</label>Multidisciplinary Pain Center, Neuroscience Center, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, <country>Denmark</country></aff><aff id="aff4"><label>d</label>Department of Economics, University of Southern Denmark, Odense, <country>Denmark</country></aff><aff id="aff5"><label>e</label>Department of Clinical Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, <country>Denmark</country></aff><aff id="aff6"><label>f</label>Department of Drug Design and Pharmacology, Copenhagen University Hospitals, Copenhagen, <country>Denmark</country></aff><aff id="aff7"><label>g</label>Department of Regional Health Research, University of Southern Denmark, Odense, <country>Denmark</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Address: Multidisciplinary Pain Clinic, Friklinikken, Region Syddanmark, Engparken 1, 7200 Grindsted, Denmark. Tel.: 0045 21946539. E-mail address: <email>d242217@dadlnet.dk</email> (K. Bested).</corresp></author-notes><pub-date pub-type="collection"><season>Jul-Aug</season><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>6</month><year>2023</year></pub-date><volume>8</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">437674</issue-id><elocation-id>e1080</elocation-id><history><date date-type="received"><day>19</day><month>10</month><year>2022</year></date><date date-type="rev-recd"><day>26</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>15</day><month>01</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-30 15:25:23.007"><day>30</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="painreports-8-e1080.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="painreports-8-e1080.pdf"/><abstract abstract-type="toc"><p>Supplemental Digital Content is Available in the Text.</p></abstract><abstract><title>Abstract</title><sec><title>Introduction:</title><p>Fibromyalgia (FM) is a chronic fluctuating, nociplastic pain condition. Naltrexone is a &#181;-opioid-receptor antagonist; preliminary studies have indicated a pain-relieving effect of low-dose naltrexone (LDN) in patients with FM. The impetus for studying LDN is the assumption of analgesic efficacy and thus reduction of adverse effects seen from conventional pharmacotherapy.</p></sec><sec><title>Objectives:</title><p><italic toggle="yes">First</italic>, to examine if LDN is associated with analgesic efficacy compared with control in the treatment of patients with FM. <italic toggle="yes">Second</italic>, to ascertain the analgesic efficacy of LDN in an experimental pain model in patients with FM evaluating the competence of the descending inhibitory pathways compared with controls. <italic toggle="yes">Third,</italic> to examine the pharmacokinetics of LDN.</p></sec><sec><title>Methods:</title><p>The study used a randomized, double-blind, placebo-controlled, crossover design and had a 3-phase setup. The first phase included baseline assessment and a treatment period (days &#8722;3 to 21), the second phase a washout period (days 22&#8211;32), and the third phase a baseline assessment followed by a treatment period (days 33&#8211;56). Treatment was with either LDN 4.5 mg or an inactive placebo given orally once daily. The primary outcomes were Fibromyalgia Impact Questionnaire revised (FIQR) scores and summed pain intensity ratings (SPIR).</p></sec><sec><title>Results:</title><p>Fifty-eight patients with FM were randomized. The median difference (IQR) for FIQR scores between LDN and placebo treatment was &#8722;1.65 (18.55; effect size = 0.15; <italic toggle="yes">P</italic> = 0.3). The median difference for SPIR scores was &#8722;0.33 (6.33; effect size = 0.13; <italic toggle="yes">P</italic> = 0.4).</p></sec><sec><title>Conclusion:</title><p>Outcome data did not indicate any clinically relevant analgesic efficacy of the LDN treatment in patients with FM.</p></sec></abstract><kwd-group><title>Keywords:</title><kwd>Low-dose naltrexone</kwd><kwd>Fibromyalgia patients</kwd><kwd>Chronic pain</kwd><kwd>RCT</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>1. Introduction</title><p>Low-dose naltrexone (LDN), in daily doses of 1 to 5 mg,<sup><xref rid="R45" ref-type="bibr">45</xref></sup> is, due to its potential analgesic and anti-inflammatory effects, increasingly used as an off-label treatment of fibromyalgia (FM) and some autoimmune pain conditions.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R57" ref-type="bibr">57</xref></sup> Naltrexone is well-known for its use in the treatment of opioid and alcohol addiction in daily doses of at least 50 mg. Naltrexone is a &#181;-opioid-receptor antagonist with, to a lesser extent, &#948;-receptor antagonistic properties, bearing a close structural similarity to naloxone. Increased oral bioavailability and longer half-life (T<sub>1/2&#946;</sub>) for the active metabolite 6&#946;-naltrexol makes naltrexone pharmacologically preferable over naloxone.<sup><xref rid="R57" ref-type="bibr">57</xref></sup> Recent experimental studies have demonstrated that LDN acts as an immune modulator in the CNS.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> Low-dose naltrexone has been used in disorders with a putative significant neuroinflammatory component, eg, chronic pelvic pain, CRPS (complex regional pain syndrome), interstitial cystitis, epilepsy, FM, inflammatory bowel disease, and multiple sclerosis.<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R57" ref-type="bibr">57</xref></sup></p><p>Fibromyalgia is a chronic, nociplastic,<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> musculoskeletal disease with an unknown etiology characterized by widespread fluctuating pain, fatigue, low quality of sleep, and high incidences of depression and anxiety disorders.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup> In Europe and the United States, 2% to 8% of the population experience FM,<sup><xref rid="R12" ref-type="bibr">12</xref></sup> affecting women more frequently than men.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R55" ref-type="bibr">55</xref></sup> The main drug classes recommended in FM are antidepressants, anticonvulsants, and opioids.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R30" ref-type="bibr">30</xref></sup> Although demonstrating clear evidence for analgesic efficacy, these drugs are associated with a risk of initiating severe arrhythmias, cardiac dysfunction, neuropsychiatric disorders, serotonergic syndrome, and enhanced postoperative morbidity.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Anticonvulsants have been recommended as alternatives associated with the development of dependence, substance abuse, and suicidality.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup> European League Against Rheumatism (EULAR) recommends that tramadol can be used in severe pain when nonpharmacological multimodal therapies fail.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> Paradoxically, in clinical FM studies, opioids generally demonstrate limited analgesic efficacy,<sup><xref rid="R15" ref-type="bibr">15</xref></sup> but because tramadol also has serotonin-norepinephrine reuptake Inhibitor (SNRI) properties, this may explain the observed weak analgesic effect. All opioids, including tramadol,<sup><xref rid="R40" ref-type="bibr">40</xref></sup> carry a risk for the development of tolerance, dependence, and substance abuse, highlighted by the &#8220;opioid epidemic&#8221; in the United States.<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R47" ref-type="bibr">47</xref></sup></p><p>Small-scale studies<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R56" ref-type="bibr">56</xref></sup> indicate analgesic efficacy of LDN with few adverse effects, and thus, our rationale for this study was to corroborate the findings in a higher volume.</p><p>Only 6 studies address LDN as a treatment of FM. For example, a pilot study by Younger et al. described lowered symptoms in all included 10 patients with FM when receiving LDN.<sup><xref rid="R55" ref-type="bibr">55</xref></sup> A randomized, double-blind, placebo-controlled study also by Younger et al.<sup><xref rid="R56" ref-type="bibr">56</xref></sup> showed a significant decrease in pain intensity in 31 included patients with FM. A study investigating the dose&#8211;response relationship among 25 patients with FM<sup><xref rid="R10" ref-type="bibr">10</xref></sup> found that 4.5 mg/day was effective in 95%. A study including 8 patients with FM showed a decrease in proinflammatory cytokines and less pain and symptoms after 8 weeks of LDN treatment.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> An explorative study describing cold pressor test (CPT) to measure pain included 15 patients with FM and showed improved scores after receiving LDN.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Finally, an explorative study using CPT in patients with chronic opioid treatment showed improved CPT scores among 21 patients with FM after LDN treatment.<sup><xref rid="R22" ref-type="bibr">22</xref></sup></p><p>The main objectives of this study were as follows: <italic toggle="yes">First</italic>, to examine if LDN was associated with a higher analgesic efficacy and improvement in physical function score compared with placebo. <italic toggle="yes">Second</italic>, to ascertain the analgesic efficacy of LDN in experimental pain procedures using quantitative somatosensory testing.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup>
<italic toggle="yes">Third,</italic> to examine the pharmacokinetics of LDN and the main metabolite 6&#946;-<italic toggle="yes">naltrexol</italic>.</p></sec><sec id="s2"><title>2. Methods</title><sec id="s2-1"><title>2.1. Study management</title><p>The Committee of Health Research Ethics of The Region of Southern Denmark (S-20150159), the Danish Medicines Agency (2015102044), and the Data Inspection Authority of The Region of Southern Denmark (2008-58-0035) approved the study protocol. The study was registered in EUDRACT (2015-002972-26) and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02806440">NCT02806440</ext-link>) and conducted in accordance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP).</p></sec><sec id="s2-2"><title>2.2. Investigational centers</title><p>The study was planned as a 2-center collaboration between The Multidisciplinary Pain Center at Rigshospitalet, Copenhagen (MPC-C), a tertiary university facility, and The Multidisciplinary Pain Clinic at Friklinikken, Grindsted, (MPC-G), a secondary health care facility. In total, an enrollment of 140 patients with FM was planned, with 70 patients with FM allocated at each investigational center. Due to organizational changes at MPC-C, only 1 patient was randomized at MPC-C. This patient made a withdrawal of consent after intake of 1 tablet. The study continued as 1 investigational center, MPC-G, planned to include 70 patients with FM.</p></sec><sec id="s2-3"><title>2.3. Study design</title><sec id="s2-3-1"><title>2.3.1. Study setting</title><p>The study was an investigator-initiated and investigator-driven study using a block-randomized, double-blind, placebo-controlled, crossover design (see Fig. <xref rid="F1" ref-type="fig">1</xref> showing overview of study). The patients with FM were randomized to treatment with LDN or placebo in the first or second treatment period. The patients with FM were randomized and allocated equally according to computer random table method. The pharmacy managed the randomization sequence generated by a web-based randomization site.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> The sequence was generated using the second generator function, applying blocks of 10 and balanced permutations (see text, Supplemental Digital Content 1, text describing study setting, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Consort (2010) flow diagram, patient selection, and eligibility. LDN, low-dose naltrexone.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="painreports-8-e1080-g001.jpg"/></fig><p>The randomization lists were stored in secure and locked confines, only accessible by the principal investigator. In case of a medical emergency, the code could be individually unblinded. Patients with FM were included consecutively and evenly over time. New patients with new randomization numbers were allocated to replace dropouts. Patients, study staff, and staff in pain clinic were blinded throughout the study period. The study was executed transparently and presented in accordance with CONSORT guidelines. Information and data collection from patients were done by 5 trained staff members. Study data were manually entered into an electronic case report form (e-CRF). After the last patient visit, data were stored in OPEN, a dedicated research registry in The Region of Southern Denmark (see text, Supplemental Digital Content 1, text describing study setting and source data, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p></sec></sec><sec id="s2-4"><title>2.4. Outcomes</title><sec id="s2-4-1"><title>2.4.1. Primary outcomes</title><p>The primary outcomes were patients with FM reporting on function, total impact, and symptoms in Fibromyalgia Impact Questionnaire revised (FIQR)<sup><xref rid="R5" ref-type="bibr">5</xref></sup> questionnaire (cf. 2.8.2.1) and reporting on pain intensity using the summed pain intensity ratings (SPIR)<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> (cf. 2.8.2.2).</p></sec><sec id="s2-4-2"><title>2.4.2. Secondary outcomes</title><p>The secondary outcomes were as follows:<list list-type="simple"><list-item><p>(1) Diary-based questionnaires; Brief Pain Inventory-Short Form (BPI-SF),<sup><xref rid="R51" ref-type="bibr">51</xref></sup> Daily Sleep Interference Scale (DSIS),<sup><xref rid="R48" ref-type="bibr">48</xref></sup> Hospital Anxiety and Depression Scale (HADS),<sup><xref rid="R58" ref-type="bibr">58</xref></sup> PainDETECT Questionnaire (PD-Q),<sup><xref rid="R16" ref-type="bibr">16</xref></sup> and Pain Catastrophizing Scale (PCS)<sup><xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup> (cf. 2.8.2.3)</p></list-item><list-item><p>(2) Quantitative Somatosensory Testing (QST)<sup><xref rid="R28" ref-type="bibr">28</xref></sup> paradigms (cf. 2.9)</p></list-item><list-item><p>(3) Pharmacokinetics of naltrexone and the main metabolite 6&#946;-naltrexol (cf. 2.10.2)</p></list-item></list></p></sec><sec id="s2-4-3"><title>2.4.3. Timeline</title><p>The study had a 3-phase setup (see Fig. <xref rid="F2" ref-type="fig">2</xref> showing study phases). The first phase included baseline assessment (BA1) (day &#8722;3 to day 1) and a treatment period (day 1 to day 21) including an outcome assessment (OA1). The second phase was a washout period (day 22 to day 32). The third phase included a baseline assessment (BA2) (day 33 to day 36) followed by a treatment period (day 36 to day 56) including an outcome assessment (OA2). The patients with FM attended 6 separate examination days (see Table <xref rid="T1" ref-type="table">1</xref>, showing overview of the study).</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Study design. Patients were randomized and allocated in a double-blind design to follow (A) or (B). The 2 treatment periods were identical (21 days) and separated by a washout period (14 &#177; 2 days). Before each treatment period, baseline assessments (questionnaires, experimental pain testing, and blood samples) were performed, providing a clinical status of the patient.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="painreports-8-e1080-g002.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Overview of the study showing the 3 phases including 2 treatment periods separated by the washout period.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="painreports-8-e1080-i001.jpg"/>
</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>The first and second baseline assessment (BA1/BA2) and the first and second outcome assessment (OA 1/OA 2) are shown. Detailed day-by-day timetable for the completion of examination days, study questionnaires, pain ratings, blood sampling, quantitative sensory testing, diary, and medication are shown.</p></fn><fn fn-type="other"><p>BA1, baseline assessment period 1; BA2, baseline assessment period 2; BPI, Brief Pain Inventory - Short Form; CPM, conditioned pain modulation; Diary, days for completion the diary; DSIS, Daily Sleep Interference Scale; FIQR, Fibromyalgia Impact Questionnaire revised; HADS, Hospital Anxiety and Depression Scale; Medication, days with consumption of project medication LDN/Placebo; OA1, outcome assessments period 1; OA2, outcome assessments period 2; PCS, pain catastrophizing scale; PPT, pain pressure threshold; PD-Q, PainDetect Questionnaire; QST Hyperalgesia + Allodynia, heat/capsaicin test; SPIR, summed pain intensity rating.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s2-5"><title>2.5. Drugs</title><p>Naltrexone (4.5 mg) and identical placebo tablets were manufactured and packed in a blinded and randomized fashion by the pharmacy (magistral production, Glostrup Apotek, Copenhagen, Denmark). Naltrexone (4.5 mg) is not marketed in Denmark but manufactured by permission of the Danish Medicines Agency (DMA), controlling the authorization and licensing of the manufacturing process according to GMP. Naltrexone 4.5 mg was chosen for this study because it is the typically applied dosage in existing studies.<sup><xref rid="R39" ref-type="bibr">39</xref>,<xref rid="R56" ref-type="bibr">56</xref></sup></p></sec><sec id="s2-6"><title>2.6. Patients</title><p>All patients with FM were screened by a medical specialist in rheumatology and fulfilled the ACR's (American College of Rheumatology) 2011 criteria of FM<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R52" ref-type="bibr">52</xref>&#8211;<xref rid="R54" ref-type="bibr">54</xref></sup> before enrollment in the study. The patients with FM were recruited from the patient registries at MPC-G.</p><sec id="s2-6-1"><title>2.6.1. Inclusion and exclusion criteria</title><p>Inclusion and Exclusion criteria are indicated in Table <xref rid="T2" ref-type="table">2</xref> (see Table <xref rid="T2" ref-type="table">2</xref>, showing inclusion and exclusion criteria).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Inclusion and exclusion criteria.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1">Inclusion criteria</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8805;18 y of age</td></tr><tr><td rowspan="1" colspan="1">&#8195;Diagnosed with fibromyalgia according to the criteria of ACR<xref rid="tblfn1" ref-type="table-fn">*</xref> by a rheumatologist</td></tr><tr><td rowspan="1" colspan="1">&#8195;Premenopausal women in contraceptive treatment<xref rid="tblfn2" ref-type="table-fn">&#8224;</xref> or sterilized</td></tr><tr><td rowspan="1" colspan="1">&#8195;Patient referred to multidisciplinary pain treatment</td></tr><tr><td rowspan="1" colspan="1">Exclusion criteria</td></tr><tr><td rowspan="1" colspan="1">&#8195;Other inflammatory rheumatologic diseases</td></tr><tr><td rowspan="1" colspan="1">&#8195;Pregnant/lactating</td></tr><tr><td rowspan="1" colspan="1">&#8195;Opioid treatment</td></tr><tr><td rowspan="1" colspan="1">&#8195;Cancer diagnosis</td></tr><tr><td rowspan="1" colspan="1">&#8195;Unstable analgesic medication<xref rid="tblfn3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td rowspan="1" colspan="1">&#8195;Non-proficient in Danish or English</td></tr><tr><td rowspan="1" colspan="1">&#8195;Allergy towards opioids</td></tr><tr><td rowspan="1" colspan="1">&#8195;Severe hepatic insufficiency</td></tr><tr><td rowspan="1" colspan="1">&#8195;Severe renal insufficiency</td></tr><tr><td rowspan="1" colspan="1">&#8195;Acute pancreatitis</td></tr><tr><td rowspan="1" colspan="1">&#8195;Patients were withdrawn from the study if the investigator/sub-investigator deemed it necessary due to medical reasons.</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="tblfn1"><label>*</label><p>American College of Rheumatology (2011 Wolfe F, H&#228;user W. Fibromyalgia diagnosis and diagnostic criteria. Ann Med 2011; 43:495&#8211;502).</p></fn><fn fn-type="other" id="tblfn2"><label>&#8224;</label><p>Contraceptives defined as spiral or hormonal contraceptive drugs (birth control tablets, implants, transdermal depot patches, vaginal ring, or injectable depot).</p></fn><fn fn-type="other" id="tblfn3"><label>&#8225;</label><p>Paracetamol rescue is accepted (requires registration in the diary).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s2-7"><title>2.7. Concomitant treatment</title><p>Concomitant medications were registered in the e-CRF, including generic names and doses. Paracetamol was used as rescue medication (1 g maximum 3 times a day).</p></sec><sec id="s2-8"><title>2.8. Study chronology</title><sec id="s2-8-1"><title>2.8.1. Diary</title><p>The patients with FM received a diary that allowed entries concerning study medication, adverse events, pain assessment forms, questionnaires, and adverse events.</p></sec><sec id="s2-8-2"><title>2.8.2. Questionnaires</title><p>The questionnaires were self-reported. Patients were contacted by phone the day before answering the first questionnaire.</p><sec id="s2-8-2-1"><title>2.8.2.1. Fibromyalgia impact questionnaire revised</title><p>The FIQR<sup><xref rid="R5" ref-type="bibr">5</xref></sup> is a tool developed to assess FM-related problems and response to a given treatment. The FIQR was translated from the original English version to Danish by 4 health care professionals specialized in the management of chronic pain. The back-translation was then performed by a native English individual fluent in Danish. After revision and back-translation, a final revised Danish version of FIQR was generated. The FIQR explores 3 domains: function, total impact, and symptoms. The patient was asked to answer based on the experience during the last 7 days before filling in the questionnaire. The questionnaire includes 21 questions regarding everyday activities. The patient was asked to mark the degree of difficulty spanning from &#8220;no difficulty&#8221; to &#8220;very difficult performing the activity.&#8221; Furthermore, the questionnaire evaluated whether the patient was restricted or incapacitated in doing the weekly chores by the FM symptoms. The FIQR also assessed current pain intensity, energy level, sleep quality, anxiety symptoms, feeling depressed, body stiffness, sensitivity to touch, difficulties with balance, memory, and with the perception of loud, shrill noises, smells, or cold.</p><p>The FIQR scoring was made by dividing the function domain sum (0&#8211;90 points) by 3. The overall impact domain was left unchanged (0&#8211;20 points). The symptom domain sum (0&#8211;100 points) was divided by 2. The 3 domain scores were then summed (0&#8211;100 points). Differences in mean score in FIQR between BA1 (day &#8722;3 and day 1) and BA2 (day 33 and day 36) and between OA1 (day 18 and day 21) and OA2 (day 53 and day 56), respectively, were calculated.</p></sec><sec id="s2-8-2-2"><title>2.8.2.2. Numeric rating scale, summed pain intensity rating</title><p>The 11-point numeric rating scale (NRS)<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> was applied to evaluate pain intensity (during rest, personal hygiene measures, and activity of daily living). The patient with FM indicated the pain intensity (0&#8211;10; 0 = &#8220;no pain&#8221;; 10 = &#8220;worst possible pain&#8221;) based on the experience during the last 24 hours before filling in the questionnaire. The NRS ratings across each activity were summed as SPIR (0&#8211;30 points). Differences in mean score in SPIR between BA1 (days &#8722;2, &#8722;1, 1) and BA2 (days 34, 35, 36) and between OA1 (days 19, 20, 21) and OA2 (days 54, 55, 56), respectively, were calculated.</p></sec><sec id="s2-8-2-3"><title>2.8.2.3. Miscellaneous questionnaires</title><p>The BPI-SF,<sup><xref rid="R51" ref-type="bibr">51</xref></sup> DSIS,<sup><xref rid="R48" ref-type="bibr">48</xref></sup> HADS,<sup><xref rid="R58" ref-type="bibr">58</xref></sup> PD-Q,<sup><xref rid="R16" ref-type="bibr">16</xref></sup> and PCS<sup><xref rid="R42" ref-type="bibr">42</xref></sup> are described in detail in Supplemental Digital Content (see text, Supplemental Digital Content 2, text describing miscellaneous questionnaires, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p></sec></sec></sec><sec id="s2-9"><title>2.9. Quantitative somatosensory testing</title><p>Quantitative somatosensory testing (QST) is a standardized activation of the sensory system by the application of graded chemical, electrical, mechanical, or thermal test stimuli, with an assessment of the evoked psychophysical responses, examining sensory detection and pain thresholds.<sup><xref rid="R28" ref-type="bibr">28</xref></sup></p><sec id="s2-9-1"><title>2.9.1. Heat&#8211;capsaicin sensitization</title><p>The heat&#8211;capsaicin sensitization test is a validated experimental pain model investigating aspects of central sensitization, eg, secondary hyperalgesia and allodynia<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R38" ref-type="bibr">38</xref></sup> (see text, Supplemental Digital Content 3, text describing quantitative somatosensory testing, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p></sec><sec id="s2-9-2"><title>2.9.2. Pressure pain thresholds</title><p>Assessments of pressure pain thresholds (PPTs) were performed with a calibrated pressure algometer<sup><xref rid="R34" ref-type="bibr">34</xref></sup> (see text, Supplemental Digital Content 3, text describing quantitative somatosensory testing, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p></sec><sec id="s2-9-3"><title>2.9.3. Conditioned pain modulation test</title><p>The conditioned pain modulation (CPM) test evaluates the efficiency of the descending inhibitory pathways and has been used as a quantitative measure of pain disinhibition in patients with FM.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> The CPM test was performed as a cold pressor test; PPT1 was the baseline assessment, and PPT2 the assessment measured after the patient had submerged their left hand in cold water for 60 seconds (see text, Supplemental Digital Content 3, text describing quantitative somatosensory testing, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p><p>The CPM efficiency was calculated as follows:<disp-formula id="MU1"><mml:math id="M1" overflow="scroll"><mml:mrow><mml:mtext>CPM&#160;efficiency&#160;</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mtext>%</mml:mtext><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>100</mml:mn><mml:mtext>%</mml:mtext><mml:mo>&#215;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:mi>T</mml:mi><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p></sec></sec><sec id="s2-10"><title>2.10. Blood Sampling</title><sec id="s2-10-1"><title>2.10.1. Routine blood chemistry</title><p>Screening of kidney and liver function was tested before inclusion in the study according to safety criteria.</p></sec><sec id="s2-10-2"><title>2.10.2. Naltrexone and 6&#946;-naltrexol plasma concentration measurements</title><p>To examine the pharmacokinetics (PK) of naltrexone and its main metabolite, 6&#946;-naltrexol, venous blood samples were collected in lithium-heparin&#8211;containing tubes on days 1, 14, 21, 36, 49, and 56 (see text, Supplemental Digital Content 4, text describing blood sampling and analysis, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p><p>On days 1 and 36 (first day of treatment periods), samples were collected in the morning just before the intake of the first tablet and then subsequently at 15, 30, 45, and 60 minutes after tablet intake. On days 14, 21, 49, and 56, medication was taken in the morning, and samples were collected during the clinical visit 1 to 3 hours later.</p></sec></sec><sec id="s2-11"><title>2.11. Adverse events</title><p>Definitions, monitoring, and reporting procedures are described in Supplemental Digital Content 5 (see text, Supplemental Digital Content 5, text describing adverse events, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p><sec id="s2-11-1"><title>2.11.1. Safety</title><p>Low-dose naltrexone is considered safe to administer. Four studies<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R55" ref-type="bibr">55</xref>&#8211;<xref rid="R57" ref-type="bibr">57</xref></sup> only reported mild adverse events. The following adverse events were specifically asked for and reported: sleep disturbances, vivid dreams, nausea, diarrhea, headache, and tiredness.</p></sec></sec><sec id="s2-12"><title>2.12. Statistics</title><sec id="s2-12-1"><title>2.12.1. Statistical significance</title><p>The authors are aware of the discussions concerning the indiscriminate use of <italic toggle="yes">P</italic> values as an absolute mean of null hypothesis testing.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R49" ref-type="bibr">49</xref>,<xref rid="R50" ref-type="bibr">50</xref></sup> In this article, the term statistical significance was avoided. The advice &#8220;correct and careful interpretation of statistical tests demands examining the sizes of effect estimates and confidence limits, as well as precise <italic toggle="yes">P</italic> values (not just whether <italic toggle="yes">P</italic> values are above or below 0.05 or some other threshold)&#8221; was generally followed.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup></p></sec><sec id="s2-12-2"><title>2.12.2. Sample size estimates</title><p>The calculation is based on FIQ data from Younger et al.,<sup><xref rid="R56" ref-type="bibr">56</xref></sup> where mean values (SD) in the LDN group of 28.8 (12.5)% and in the placebo group of 18.0 (14.6)% are given for pain reduction, which gives an effect size (ES) of 0.61 (GPower*3.1.9.2, Kiel University, Germany).</p><p>The sample size estimates were based on a 1% chance of type &#8544; errors (&#945; = 0.01), 10% chance of type &#8545; errors (&#946; = 0.10), nonparametric distribution (ARE-correction; paired analysis with Wilcoxon signed-rank test), and an estimated correlation coefficient (<italic toggle="yes">r</italic>) between the treatments of 0.3. The estimated sample size per center was 51, allowing complete analyses to be performed at each center (see text, Supplemental Digital Content 6, text describing statistics, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>).</p></sec><sec id="s2-12-3"><title>2.12.3. Statistical data processing</title><p>Our analyses focused on measuring the pharmacodynamics effects of LDN compared with placebo on a number of primary and secondary outcomes. We exploited our access to both baseline and outcome measures for all individuals under both active treatment and placebo. This allowed us to perform paired tests. First, baseline (BA) and outcome (OA) measures were transformed into measures of changes (&#916;) for all variables (<italic toggle="yes">v</italic>) and for all individuals (<italic toggle="yes">i</italic>) under treatment with LDN or placebo:<disp-formula id="MU2"><mml:math id="M2" overflow="scroll"><mml:mrow><mml:mi>&#916;</mml:mi><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>&#8722;</mml:mo><mml:msubsup><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>B</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>To assess the pharmacodynamics effects of LDN, the differences between LDN treatment and placebo were examined (see text, Supplemental Digital Content 6, text describing statistics, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>). Formally testing the null hypotheses of no effects, paired Wilcoxon signed-rank tests were used to report the associated <italic toggle="yes">P</italic> values and appropriate ES. For completeness, the results of the corresponding parametric tests were reported in tabular form (mean [SD], <italic toggle="yes">P</italic>, 95% confidence interval [CI], effect sizes [ESs]). Data are reported as median (IQR) unless otherwise stated.</p></sec></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3-1"><title>3.1. Patients</title><p>A total of 151 patients with FM were assessed for eligibility, and 58 patients with FM were included and randomized. Sixty patients declined to participate mostly due to time requirement, and 33 did not meet inclusion criteria. Two patients with FM dropped out due to adverse events (nausea, vomiting) immediately after the treatment started. One patient dropped out due to concomitant acute illness, and 3 patients with FM did not state the withdrawal reason. Fifty-two patients with FM fulfilled the study per protocol. The first patient was included in May 2016, and the last patient visit was in December 2019. Inclusion was evenly distributed over time.</p><sec id="s3-1-1"><title>3.1.1. Concomitant medication and demographics</title><p>Demographic data and use of concomitant medication are described in Table <xref rid="T3" ref-type="table">3</xref> (see Table <xref rid="T3" ref-type="table">3</xref> describing demographic) and Table <xref rid="T4" ref-type="table">4</xref> (see Table <xref rid="T4" ref-type="table">4</xref> describing concomitant medication), respectively. The patients with FM continued the medication in stable doses during the study.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Demographics data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Demographics</th><th rowspan="1" colspan="1">Value</th><th rowspan="1" colspan="1">Mean</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male/female, n</td><td rowspan="1" colspan="1">6/46</td><td rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">Age min/max, y</td><td rowspan="1" colspan="1">24/66</td><td rowspan="1" colspan="1">50.4</td></tr><tr><td rowspan="1" colspan="1">BMI min/max, kg/m<sup>2</sup></td><td rowspan="1" colspan="1">20/41</td><td rowspan="1" colspan="1">31.2</td></tr><tr><td rowspan="1" colspan="1">Weight min/max, kg</td><td rowspan="1" colspan="1">52/130</td><td rowspan="1" colspan="1">86.5</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>BMI, body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Concomitant medication.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Concomitant medication</th><th rowspan="1" colspan="1">n<xref rid="tblfn4" ref-type="table-fn">*</xref></th><th rowspan="1" colspan="1">DD<xref rid="tblfn5" ref-type="table-fn">&#8224;</xref> mg</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Paracetamol<xref rid="tblfn6" ref-type="table-fn">&#8225;</xref></td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">500</td></tr><tr><td rowspan="1" colspan="1">Paracetamol<xref rid="tblfn7" ref-type="table-fn">&#167;</xref></td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">1000&#8211;4000</td></tr><tr><td rowspan="1" colspan="1">Tizanidine</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">2&#8211;10</td></tr><tr><td rowspan="1" colspan="1">Baclofen</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">10&#8211;20</td></tr><tr><td rowspan="1" colspan="1">Chlorzoxazone</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">375&#8211;1500</td></tr><tr><td rowspan="1" colspan="1">Gabapentin</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">60&#8211;800</td></tr><tr><td rowspan="1" colspan="1">Pregabalin</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">150&#8211;300</td></tr><tr><td rowspan="1" colspan="1">Lamotrigine</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">200</td></tr><tr><td rowspan="1" colspan="1">Topiramate</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">200</td></tr><tr><td rowspan="1" colspan="1">Amitriptyline</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">10&#8211;90</td></tr><tr><td rowspan="1" colspan="1">Duloxetine</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">60&#8211;120</td></tr><tr><td rowspan="1" colspan="1">Venlafaxine</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">75&#8211;300</td></tr><tr><td rowspan="1" colspan="1">Citalopram</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">20&#8211;40</td></tr><tr><td rowspan="1" colspan="1">Sertraline</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">100</td></tr><tr><td rowspan="1" colspan="1">Levodopa</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">125</td></tr><tr><td rowspan="1" colspan="1">Melatonin</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Eletriptan<xref rid="tblfn6" ref-type="table-fn">&#8225;</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">40</td></tr><tr><td rowspan="1" colspan="1">Sumatriptan<xref rid="tblfn6" ref-type="table-fn">&#8225;</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">100</td></tr><tr><td rowspan="1" colspan="1">Metformin</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1000</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="tblfn4"><label>*</label><p>Number of patients with intake.</p></fn><fn fn-type="other" id="tblfn5"><label>&#8224;</label><p>Daily dose.</p></fn><fn fn-type="other" id="tblfn6"><label>&#8225;</label><p>Prn.</p></fn><fn fn-type="other" id="tblfn7"><label>&#167;</label><p>Fixed daily dose.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-1-2"><title>3.1.2. Adverse events</title><p>Adverse events (see text, Supplemental Digital Content 5, text describing adverse events, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>) were registered at visit days in both treatment periods. Headache, fatigue, nausea, and dizziness were registered in both treatment periods by a small number of patients with FM, and all adverse events were classified as minor (See Table <xref rid="T5" ref-type="table">5</xref> describing adverse events). The 2 patients with FM who dropped out immediately after the start of the treatment experienced minor adverse events.</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>Patients reported adverse events.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Adverse event</th><th rowspan="1" colspan="1">LDN treatment (n)</th><th rowspan="1" colspan="1">Placebo treatment (n)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">Fatigue</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Nausea</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">Dizziness</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Stomach ache</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Diarrhea</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Constipation</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Blurry vision</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Worsened sleep</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Improved sleep</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Pain more intense</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Adverse events reported in dairy by patient during each treatment period (n = 52). All adverse events were classified as minor, and no serious adverse events or suspected unexpected adverse reactions occurred.</p></fn><fn fn-type="other"><p>LDN, low-dose naltrexone.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3-2"><title>3.2. Primary outcome</title><sec id="s3-2-1"><title>3.2.1. Fibromyalgia impact questionnaire revised</title><p>Baseline and outcome scores for FIQR were obtained under both LDN and placebo treatment (n = 50). The differences were &#8722;1.65 (18.55) (see Fig. <xref rid="F3" ref-type="fig">3</xref> dot-line diagram showing scores). The Wilcoxon signed-rank test did not indicate any difference between LDN and placebo (ES = 0.15, CI = &#8722;6.72 to 2.15; <italic toggle="yes">P</italic> = 0.30; see Table <xref rid="T6" ref-type="table">6</xref> describing FIQR results). The random effects model did not indicate any difference between LDN and placebo (conditional mean difference &#8722;2.50, <italic toggle="yes">P</italic> = 0.34) (see text, Supplemental Digital Content 6, text describing statistical data processing, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>; see Table <xref rid="T7" ref-type="table">7</xref> describing absolute measures).</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Dot-line diagram presenting change in FIQR score (left panel) and SPIR score (right panel) after LDN treatment and placebo treatment. Each line represents a patient, mean and median values for all patients shown in bottom of figure. Negative values (below 0) indicate improvements. Black dashed line indicates mean value at LDN and placebo treatment. FIQR, Fibromyalgia Impact Questionnaire revised; LDN, low-dose naltrexone; SPIR, summed pain intensity ratings.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="painreports-8-e1080-g003.jpg"/></fig><table-wrap position="float" id="T6" orientation="portrait"><label>Table 6</label><caption><p>Changes in primary outcome variables from low-dose naltrexone treatment to placebo treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Outcome</th><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">Median</th><th rowspan="1" colspan="1">IQR</th><th rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th rowspan="1" colspan="1">CI (95%)</th><th rowspan="1" colspan="1">ES</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th rowspan="1" colspan="1">CI (95%)</th><th rowspan="1" colspan="1">Cohen d (ES)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">FIQR (score)</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">&#8722;1.65</td><td rowspan="1" colspan="1">18.55</td><td rowspan="1" colspan="1">0.30</td><td rowspan="1" colspan="1">&#8722;6.72, 2.15</td><td rowspan="1" colspan="1">0.15</td><td rowspan="1" colspan="1">&#8722;2.19</td><td rowspan="1" colspan="1">20.40</td><td rowspan="1" colspan="1">0.45</td><td rowspan="1" colspan="1">&#8722;7.98, 3.61</td><td rowspan="1" colspan="1">&#8722;0.11</td></tr><tr><td rowspan="1" colspan="1">SPIR (score)</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">&#8722;0.33</td><td rowspan="1" colspan="1">6.33</td><td rowspan="1" colspan="1">0.40</td><td rowspan="1" colspan="1">&#8722;2.17, 0.92</td><td rowspan="1" colspan="1">0.13</td><td rowspan="1" colspan="1">&#8722;0.23</td><td rowspan="1" colspan="1">6.48</td><td rowspan="1" colspan="1">0.24</td><td rowspan="1" colspan="1">&#8722;2.18, 1.72</td><td rowspan="1" colspan="1">&#8722;0.04</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ES, effect size; FIQR, Fibromyalgia Impact Questionnaire revised; IQR, interquartile range; n, number of patients; SPIR, summed pain intensity rating.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T7" orientation="portrait"><label>Table 7</label><caption><p>Changes in primary outcome variables.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Outcome</th><th colspan="2" rowspan="1">BA1<break/>n = 52</th><th colspan="2" rowspan="1">OA1<break/>n = 52</th><th colspan="2" rowspan="1">Change from BA1 to OA1</th><th colspan="2" rowspan="1">BA2<break/>n = 51</th><th colspan="2" rowspan="1">OA2<break/>n = 51</th><th colspan="2" rowspan="1">Change from BA2 to OA2</th></tr><tr><th rowspan="1" colspan="1">FIQR score (0&#8211;100)</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">LDN treatment</td><td rowspan="1" colspan="1">53.8</td><td rowspan="1" colspan="1">2.4</td><td rowspan="1" colspan="1">48.7</td><td rowspan="1" colspan="1">3.5</td><td rowspan="1" colspan="1">&#8722;5.0</td><td rowspan="1" colspan="1">2.8</td><td rowspan="1" colspan="1">49.8</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">46.7</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">&#8722;3.0</td><td rowspan="1" colspan="1">2.7</td></tr><tr><td rowspan="1" colspan="1">Placebo treatment</td><td rowspan="1" colspan="1">52.1</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">46.5</td><td rowspan="1" colspan="1">3.9</td><td rowspan="1" colspan="1">&#8722;5.6</td><td rowspan="1" colspan="1">3.0</td><td rowspan="1" colspan="1">53.8</td><td rowspan="1" colspan="1">3.3</td><td rowspan="1" colspan="1">56.3</td><td rowspan="1" colspan="1">3.3</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">1.5</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Outcome</th><th colspan="2" rowspan="1">BA1<break/>n = 48</th><th colspan="2" rowspan="1">OA1<break/>n = 48</th><th colspan="2" rowspan="1">Change from BA1 to OA1</th><th colspan="2" rowspan="1">BA2<break/>n = 44</th><th colspan="2" rowspan="1">OA2<break/>n = 44</th><th colspan="2" rowspan="1">Change from BA2 to OA2</th></tr><tr><th rowspan="1" colspan="1">SPIR score (0&#8211;30)</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">LDN treatment</td><td rowspan="1" colspan="1">16.6</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">15.4</td><td rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">&#8722;1.2</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">16.2</td><td rowspan="1" colspan="1">1.0</td><td rowspan="1" colspan="1">15.4</td><td rowspan="1" colspan="1">1.0</td><td rowspan="1" colspan="1">&#8722;0.8</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1">Placebo treatment</td><td rowspan="1" colspan="1">17.1</td><td rowspan="1" colspan="1">1.0</td><td rowspan="1" colspan="1">15.3</td><td rowspan="1" colspan="1">1.4</td><td rowspan="1" colspan="1">&#8722;1.7</td><td rowspan="1" colspan="1">1.1</td><td rowspan="1" colspan="1">17.6</td><td rowspan="1" colspan="1">1.1</td><td rowspan="1" colspan="1">18.1</td><td rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">0.4</td><td rowspan="1" colspan="1">0.8</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>FIQR, Fibromyalgia Impact Questionnaire revised; SPIR, summed pain intensity rating, absolute values.</p></fn><fn fn-type="other"><p>Scores of FIQR respectively SPIR at BA1, baseline assessment 1; OA1, outcome assessment 1; BA2, baseline assessment 2; OA2, outcome assessment 2; n, number of patients.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2-2"><title>3.2.2. Summed pain intensity ratings</title><p>The difference in SPIR scores between LDN and placebo was &#8722;0.33 (6.33) (see Fig. <xref rid="F3" ref-type="fig">3</xref> dot-line diagram showing scores). The Wilcoxon signed-rank test revealed ES of 0.13 and CI of &#8722;2.17 to 0.92 (<italic toggle="yes">P</italic> = 0.4; see Table <xref rid="T6" ref-type="table">6</xref> describing SPIR results). The random effects model did not indicate any difference between LDN and placebo (conditional mean difference &#8722;0.40, <italic toggle="yes">P</italic> = 0.68) (see text, Supplemental Digital Content 6, text describing statistical data processing, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>; see Table <xref rid="T7" ref-type="table">7</xref> describing absolute measures).</p></sec></sec><sec id="s3-3"><title>3.3. Secondary outcomes</title><p>See Table <xref rid="T8" ref-type="table">8</xref> describing secondary outcomes results.</p><table-wrap position="float" id="T8" orientation="portrait"><label>Table 8</label><caption><p>Changes in secondary outcome variables from low-dose naltrexone treatment to placebo treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Outcome</th><th rowspan="1" colspan="1">n<xref rid="tblfn8" ref-type="table-fn">*</xref></th><th rowspan="1" colspan="1">Median</th><th rowspan="1" colspan="1">IQR</th><th rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th rowspan="1" colspan="1">CI (95%)</th><th rowspan="1" colspan="1">ES</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th rowspan="1" colspan="1">CI (95%)</th><th rowspan="1" colspan="1">Cohen d (ES)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Hyperalgesia (cm<sup>2</sup>)</td><td rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.9</td><td align="char" char="." rowspan="1" colspan="1">48.1</td><td rowspan="1" colspan="1">0.83</td><td align="char" char="." rowspan="1" colspan="1">&#8722;14.6, 12.1</td><td rowspan="1" colspan="1">0.04</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">37.2</td><td align="char" char="." rowspan="1" colspan="1">1.00</td><td align="char" char="." rowspan="1" colspan="1">&#8722;13.2, 13.2</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td rowspan="1" colspan="1">Allodynia (cm<sup>2</sup>)</td><td rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">&#8722;14.5</td><td align="char" char="." rowspan="1" colspan="1">36.5</td><td rowspan="1" colspan="1">0.17</td><td align="char" char="." rowspan="1" colspan="1">&#8722;20.8, 5.</td><td rowspan="1" colspan="1">0.24</td><td align="char" char="." rowspan="1" colspan="1">&#8722;6.7</td><td align="char" char="." rowspan="1" colspan="1">36.5</td><td align="char" char="." rowspan="1" colspan="1">0.30</td><td align="char" char="." rowspan="1" colspan="1">&#8722;19.6, 6.3</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.18</td></tr><tr><td rowspan="1" colspan="1">PPT tender (kPa)</td><td rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">0.1</td><td align="char" char="." rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">0.88</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.2, 0.2</td><td rowspan="1" colspan="1">0.03</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.0</td><td align="char" char="." rowspan="1" colspan="1">0.8</td><td align="char" char="." rowspan="1" colspan="1">0.84</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.3, 0.3</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.04</td></tr><tr><td rowspan="1" colspan="1">PPT control (kPa)</td><td rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">0.1</td><td align="char" char="." rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0.75</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.3, 0.3</td><td rowspan="1" colspan="1">0.06</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="char" char="." rowspan="1" colspan="1">0.98</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.3, 0.3</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td rowspan="1" colspan="1">CPM efficiency (%)</td><td rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">&#8722;9.3</td><td align="char" char="." rowspan="1" colspan="1">61.0</td><td rowspan="1" colspan="1">0.23</td><td align="char" char="." rowspan="1" colspan="1">&#8722;25.4, 6.9</td><td rowspan="1" colspan="1">0.21</td><td align="char" char="." rowspan="1" colspan="1">&#8722;9.3</td><td align="char" char="." rowspan="1" colspan="1">46.3</td><td align="char" char="." rowspan="1" colspan="1">0.40</td><td align="char" char="." rowspan="1" colspan="1">&#8722;25.4, 6.9</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.14</td></tr><tr><td rowspan="1" colspan="1">HADS A (score)</td><td rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">&#8722;1.0</td><td align="char" char="." rowspan="1" colspan="1">3.3</td><td rowspan="1" colspan="1">0.06</td><td align="char" char="." rowspan="1" colspan="1">&#8722;2.0, 0.0</td><td rowspan="1" colspan="1">0.28</td><td align="char" char="." rowspan="1" colspan="1">&#8722;1.0</td><td align="char" char="." rowspan="1" colspan="1">3.3</td><td align="char" char="." rowspan="1" colspan="1">0.04</td><td align="char" char="." rowspan="1" colspan="1">&#8722;2.0, 0.1</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.31</td></tr><tr><td rowspan="1" colspan="1">HADS D (score)</td><td rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">1.0</td><td align="char" char="." rowspan="1" colspan="1">3.3</td><td rowspan="1" colspan="1">0.22</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.5, 2.0</td><td rowspan="1" colspan="1">0.22</td><td align="char" char="." rowspan="1" colspan="1">0.5</td><td align="char" char="." rowspan="1" colspan="1">3.5</td><td align="char" char="." rowspan="1" colspan="1">0.32</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.5, 1.5</td><td align="char" char="." rowspan="1" colspan="1">0.14</td></tr><tr><td rowspan="1" colspan="1">PCS R (score)</td><td rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">8.0</td><td rowspan="1" colspan="1">0.65</td><td align="char" char="." rowspan="1" colspan="1">&#8722;3.0, 1.0</td><td rowspan="1" colspan="1">0.11</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.2</td><td align="char" char="." rowspan="1" colspan="1">4.7</td><td align="char" char="." rowspan="1" colspan="1">0.84</td><td align="char" char="." rowspan="1" colspan="1">&#8722;1.9, 1.5</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.04</td></tr><tr><td rowspan="1" colspan="1">PCS M (score)</td><td rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.5</td><td align="char" char="." rowspan="1" colspan="1">4.0</td><td rowspan="1" colspan="1">0.10</td><td align="char" char="." rowspan="1" colspan="1">&#8722;2.5, 0.0</td><td rowspan="1" colspan="1">0.27</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.7</td><td align="char" char="." rowspan="1" colspan="1">2.9</td><td align="char" char="." rowspan="1" colspan="1">0.17</td><td align="char" char="." rowspan="1" colspan="1">&#8722;1.8, 0.3</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.25</td></tr><tr><td rowspan="1" colspan="1">PCS H (score)</td><td rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.5</td><td align="char" char="." rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">0.48</td><td align="char" char="." rowspan="1" colspan="1">&#8722;3.5, 1.5</td><td rowspan="1" colspan="1">0.12</td><td align="char" char="." rowspan="1" colspan="1">&#8722;1.1</td><td align="char" char="." rowspan="1" colspan="1">6.6</td><td align="char" char="." rowspan="1" colspan="1">0.34</td><td align="char" char="." rowspan="1" colspan="1">&#8722;3.4, 1.2</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.16</td></tr><tr><td rowspan="1" colspan="1">DSIS (score)</td><td rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">0.2</td><td align="char" char="." rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">0.75</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.6, 1.0</td><td rowspan="1" colspan="1">0.07</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">2.5</td><td align="char" char="." rowspan="1" colspan="1">0.45</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.5, 1.2</td><td align="char" char="." rowspan="1" colspan="1">0.12</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="tblfn8"><label>*</label><p>Technical problems with the pressure algometer and the thermal analyzer reduced the available number of quantitative somatosensory assessments.</p></fn><fn fn-type="other"><p>CPM, conditioned pain modulation; DSIS, Daily Sleep Interference Scale; ES, effect size; HADS, Hospital Anxiety and Depression Scale (A = Anxiety, D = Depression); IQR, interquartile range; n, number of patients; PPT Control, pressure pain threshold at control points; PCS, pain catastrophizing scale (R = rumination, M = magnification, H = helplessness); PPT, pressure pain threshold at tender points.</p></fn></table-wrap-foot></table-wrap><sec id="s3-3-1"><title>3.3.1. Quantitative somatosensory testing</title><sec id="s3-3-1-1"><title>3.3.1.1. Secondary hyperalgesia areas</title><p>The differences in secondary hyperalgesia areas between LDN and placebo treatments (n = 33) were &#8722;0.88 (48.13) cm<sup>2</sup>. Wilcoxon signed-rank test revealed ES of 0.04 and CI of &#8722;14.63 to 12.10 (<italic toggle="yes">P</italic> = 0.83).</p></sec><sec id="s3-3-1-2"><title>3.3.1.2. Allodynia</title><p>The differences in allodynia areas between LDN and placebo treatments (n = 33) were &#8722;14.46 (42.04) cm<sup>2</sup>. Wilcoxon signed-rank test revealed ES of 0.24 and CI of &#8722;20.82 to 4.96 (<italic toggle="yes">P</italic> = 0.65).</p></sec><sec id="s3-3-1-3"><title>3.3.1.3. Pressure pain threshold</title><p>The differences in PPT (kPa) at tender points between LDN and placebo treatments (n = 32) were 0.08 (0.52) kPa. Wilcoxon signed-rank test revealed ES of 0.03 and CI and &#8722;0.21 to 0.21; <italic toggle="yes">P</italic> = 0.88. The differences in PPT at control points between LDN and placebo treatments (n = 34) were 0.08 (0.76) kPa. Wilcoxon signed-rank test revealed ES of 0.06 and CI &#8722;0.26 to 0.29 (<italic toggle="yes">P</italic> = 0.75).</p></sec><sec id="s3-3-1-4"><title>3.3.1.4. Conditioned pain modulation</title><p>The difference in CPM (%) between LDN and placebo was (n = 34) &#8722;9.25 (61.00). Wilcoxon signed-rank test revealed ES of 0.21 and CI of &#8722;25.42 to 6.93 (<italic toggle="yes">P =</italic> 0.23).</p></sec></sec><sec id="s3-3-2"><title>3.3.2. PainDETECT</title><p>The PD-Q questionnaire evaluates the likelihood of presence of a neuropathic pain component. At day 1, before treatment, 6 patients with FM scored the neuropathic component to be very unlikely, 22 that the component could not be rejected and 24 that the neuropathic was very likely.</p></sec><sec id="s3-3-3"><title>3.3.3. Miscellaneous questionnaires</title><p>Differences in scores between LDN and placebo treatment from the questionnaires for HADS, PCS, and DSIS are presented in Table <xref rid="T8" ref-type="table">8</xref> (see Table <xref rid="T8" ref-type="table">8</xref> describing scores in miscellaneous questionnaires).</p></sec></sec><sec id="s3-4"><title>3.4. Blood Samples</title><sec id="s3-4-1"><title>3.4.1. Pharmacokinetics and pharmacodynamics</title><p>Plasma concentrations (Cp) of naltrexone and 6&#946;-naltrexol on the first treatment day showed a fast absorption rate of naltrexone and a rapid conversion to 6&#946;-naltrexol for all patients with FM. The more than 10-fold increase in Cp of 6&#946;-naltrexol, compared with naltrexone, is due to first-pass metabolism<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R41" ref-type="bibr">41</xref></sup> with a high hepatic extraction ratio for the parent compound. Peak Cp were likely reached at 30 to 45 minutes after ingestion (see Fig. <xref rid="F4" ref-type="fig">4</xref> showing plasma concentrations). After 21 days of treatment, samples were taken 1 to 3 hours after tablet intake. The median Cp of naltrexone and 6&#946;-naltrexol were 0.33 &#181;g/L and 5.29 &#181;g/L, respectively. Detailed pharmacokinetic analyses were not performed due to short sampling period.</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Diagram presenting mean plasma concentrations of naltrexone and 6&#946;-naltrexol after oral intake of 4.5 mg naltrexone at times 0, 15, 30, 45, and 60 minutes. Error bars represent 95% confidence intervals, and shaded areas represent standard deviations. Mean plasma concentrations at 30 minutes were 0.66 &#181;g/L for naltrexone and 4.61 &#181;g/L for 6&#946;-naltrexol.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="painreports-8-e1080-g004.jpg"/></fig></sec></sec></sec><sec id="s4"><title>4. Discussion</title><sec id="s4-1"><title>4.1. Outcome</title><p>In this randomized controlled study, using a crossover design, 52 patients with FM fulfilling the ACR's 2011 criteria, the efficacy of treatment with LDN, were examined. The outcome data did not indicate any analgesic efficacy or improvement in physical function score related to the treatment. Using experimental tests of neuroplasticity perturbations, no differences were found related to the treatment. The pharmacokinetic analyses showed a rapid and reliable absorption of naltrexone.</p></sec><sec id="s4-2"><title>4.2. Current management strategies</title><p>It is generally agreed that management of FM requires a biopsychosocial approach, eg, cognitive behavioral therapy, education, mindfulness-based stress reduction, physical therapies, and physical exercise.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R46" ref-type="bibr">46</xref></sup> Also, pharmacotherapy is needed in patients with FM with severe pain as a component in multimodal rehabilitation.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup></p></sec><sec id="s4-3"><title>4.3. The rationale of multimodal pharmacotherapy</title><p>Multimodal analgesic pharmacotherapy includes the use of a combination of drugs, often with different pharmacological mechanisms of action. The multimodal concept may demonstrate infra- or supraadditivity, obtaining identical or better analgesic effects at lower doses of each drug compared with monotherapy. In acute pain management, the combination of paracetamol and NSAID has improved analgesic efficacy and caused a reduction in opioid requirement.<sup><xref rid="R44" ref-type="bibr">44</xref></sup> The evidence for the efficacy of multimodal pharmacotherapy in chronic pain is scarce. However, the study did not examine any potential additive analgesic effect by combining LDN with an antidepressant or anticonvulsant.</p></sec><sec id="s4-4"><title>4.4. Strengths of the study</title><p><italic toggle="yes">First</italic>, compared with the early FM studies<sup><xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R56" ref-type="bibr">56</xref></sup> on LDN, methodological aspects have been improved in this study. In the 2009 study<sup><xref rid="R55" ref-type="bibr">55</xref></sup> (n = 10), a single-blind, nonrandomized, crossover design was used with a fixed treatment sequence but with a dissimilar number of treatment weeks. In the 2013 study<sup><xref rid="R56" ref-type="bibr">56</xref></sup> (n = 31), a randomized, double-blind, placebo-controlled, counterbalanced, crossover design was used, however, also with dissimilar treatment periods, ie, 12 weeks with LDN <italic toggle="yes">vis-&#225;-vis</italic> 4 weeks with placebo, and <italic toggle="yes">no</italic> washout period between treatments. Interestingly, neither an a priori nor a <italic toggle="yes">post hoc</italic> sample size estimate was presented in any of the studies.</p><p><italic toggle="yes">Second</italic>, this study uses the validated FIQR as a primary outcome parameter, including summed resting and dynamic ADL pain ratings. These measures are considered improvements compared with the previously mentioned studies, only using unimodal nondynamic pain ratings as a primary outcome. Generally, the outcomes in this study are in agreement with the recommended patient phenotyping measures in chronic pain from IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials)<sup><xref rid="R14" ref-type="bibr">14</xref></sup> regarding psychometrics, sleep function, and fatigue. This study tested both the ascending <italic toggle="yes">excitatory</italic> pain pathways by the heat/capsaicin sensitization test and the descending <italic toggle="yes">inhibitory</italic> pathways by the CPM test.</p><p><italic toggle="yes">Third</italic>, the pharmacokinetics of LDN were analyzed.</p><p><italic toggle="yes">Fourth</italic>, a priori sample size estimates were based on the completion of 51 per-protocol treated patients with FM at 1 center, meaning that failure to complete inclusions in one of the centers would <italic toggle="yes">not</italic> jeopardize meaningful statistical analysis from the companion center.</p></sec><sec id="s4-5"><title>4.5. Weaknesses of the study</title><p><italic toggle="yes">First</italic>, the length of the study period, 60 days, may have impeded patient compliance, affecting the attrition rate and the number of dropouts. However, the original study<sup><xref rid="R56" ref-type="bibr">56</xref></sup> had a duration of 22 weeks, with 28 of 31 patients with FM completing the study, so this would probably not be an issue.</p><p><italic toggle="yes">Second</italic>, a placebo effect was anticipated, particularly in the first treatment period. The design of this study, however, does not allow an estimate of the magnitude of the placebo effect.</p><p><italic toggle="yes">Third,</italic> although patients with FM fulfilled the ACR's 2011 criteria, analysis of the neuroinflammatory component could have characterized patients with FM further.</p><p><italic toggle="yes">Fourth,</italic> analysis of the neuroinflammatory response to LDN could likely identify subgroups of responders but was beyond the scope of this study.</p><p><italic toggle="yes">Fifth,</italic> in this study, patients with FM were diagnosed by a specialist in rheumatology at least months before enrollment. To our knowledge, no literature has described the relevant start window for LDN treatment compared with the time of diagnosis.</p></sec><sec id="s4-6"><title>4.6. In summary</title><p>The recommended pharmacological management of FM, antidepressants, anticonvulsants, and opioids<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> are associated with a substantial risk of development of serious adverse effects. Low-dose naltrexone has in preliminary studies indicated an analgesic efficacy in FM with a low incidence of adverse effects. However, in this study, the analgesic efficacy of LDN was not corroborated.</p></sec></sec><sec sec-type="COI-statement"><title>Disclosures</title><p>The authors declare that the article is a transparent and accurate report of the research undertaken and that there are no conflicts of interest to disclose.</p></sec><sec><title>Appendix A. Supplemental digital content</title><supplementary-material position="float" content-type="local-data" orientation="portrait"><p>Supplemental digital content associated with this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/PR9/A195" ext-link-type="uri">http://links.lww.com/PR9/A195</ext-link>.</p></supplementary-material></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><fig id="s001" position="anchor" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="painreports-8-e1080-s001.pdf" position="float" orientation="portrait"/></fig></sec></body><back><ack><title>Acknowledgements</title><p>This study was supported by grants from the AP Moeller Foundation, the Danish Society of Anesthesiology and Intensive Care Medicine, and the Director Emil C. Hertz and Wife Inger Hertz' Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors express their gratitude to the participating patients and thanks to biochemist Dorte Aalund Olsen and medical laboratory technologist Christoffer Kleve-Roendbjerg for support in conducting this study.</p></ack><fn-group><fn fn-type="COI-statement"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="supplementary-material"><p>Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://journals.lww.com/painrpts/pages/default.aspx" ext-link-type="uri">www.painrpts.com</ext-link>).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amrhein</surname><given-names>V</given-names></name><name name-style="western"><surname>Greenland</surname><given-names>S</given-names></name><name name-style="western"><surname>McShane</surname><given-names>B</given-names></name></person-group>. <article-title>Scientists rise up against statistical significance</article-title>. <source>Nature</source><year>2019</year>;<volume>7748</volume>:<fpage>305</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-019-00857-9</pub-id><pub-id pub-id-type="pmid">30894741</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>LM</given-names></name><name name-style="western"><surname>Clauw</surname><given-names>DJ</given-names></name></person-group>. <article-title>Challenges of implementing fibromyalgia treatment guidelines in current clinical practice</article-title>. <source>Postgrad Med</source><year>2017</year>;<volume>129</volume>:<fpage>709</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">28562155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00325481.2017.1336417</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>LM</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>RM</given-names></name><name name-style="western"><surname>Crofford</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Dean</surname><given-names>LE</given-names></name><name name-style="western"><surname>Clauw</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Goldenberg</surname><given-names>DL</given-names></name><name name-style="western"><surname>Fitzcharles</surname><given-names>MA</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>ES</given-names></name><name name-style="western"><surname>Staud</surname><given-names>R</given-names></name><name name-style="western"><surname>Sarzi-Puttini</surname><given-names>P</given-names></name><name name-style="western"><surname>Buskila</surname><given-names>D</given-names></name><name name-style="western"><surname>Macfarlane</surname><given-names>GJ</given-names></name></person-group>. <article-title>AAPT diagnostic criteria for fibromyalgia</article-title>. <source>J Pain</source><year>2019</year>;<volume>6</volume>:<fpage>611</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2018.10.008</pub-id><pub-id pub-id-type="pmid">30453109</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="webpage">Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://randomization.com" ext-link-type="uri">randomization.com</ext-link>.</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>R</given-names></name><name name-style="western"><surname>Friend</surname><given-names>R</given-names></name><name name-style="western"><surname>Jones</surname><given-names>KD</given-names></name><name name-style="western"><surname>Ward</surname><given-names>R</given-names></name><name name-style="western"><surname>Han</surname><given-names>BK</given-names></name><name name-style="western"><surname>Ross</surname><given-names>RL</given-names></name></person-group>. <article-title>The revised fibromyalgia impact questionnaire (FIQR): validation and psychometric properties</article-title>. <source>Arthritis Res Ther</source><year>2009</year>;<volume>11</volume>:<fpage>415</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/ar2783</pub-id><pub-id pub-id-type="pmcid">PMC2745803</pub-id><pub-id pub-id-type="pmid">19664287</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blume</surname><given-names>JD</given-names></name><name name-style="western"><surname>D'Agostino McGowan</surname><given-names>L</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>WD</given-names></name><name name-style="western"><surname>Greevy</surname><given-names>RA</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Second-generation p-values: improved rigor, reproducibility, &amp; transparency in statistical analyses</article-title>. <source>PLoS One</source><year>2018</year>;<volume>13</volume>:<fpage>e0188299</fpage>.<pub-id pub-id-type="pmid">29565985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0188299</pub-id><pub-id pub-id-type="pmcid">PMC5863943</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borchers</surname><given-names>A</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>M</given-names></name></person-group>. <article-title>Fibromyalgia: a critical and comprehensive review</article-title>. <source>Clin Rev Allerg Immunol</source><year>2015</year>;<volume>49</volume>:<fpage>100</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12016-015-8509-4</pub-id><pub-id pub-id-type="pmid">26445775</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breivik</surname><given-names>H</given-names></name><name name-style="western"><surname>Borchgrevink</surname><given-names>P</given-names></name><name name-style="western"><surname>Allen</surname><given-names>S</given-names></name><name name-style="western"><surname>Rosseland</surname><given-names>L</given-names></name><name name-style="western"><surname>Romundstad</surname><given-names>L</given-names></name><name name-style="western"><surname>Breivik Hals</surname><given-names>E</given-names></name><name name-style="western"><surname>Kvarstein</surname><given-names>G</given-names></name><name name-style="western"><surname>Stubhaug</surname><given-names>A</given-names></name></person-group>. <article-title>Assessment of pain</article-title>. <source>Br J Anaesth</source><year>2008</year>;<volume>101</volume>:<fpage>17</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">18487245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aen103</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brietzke</surname><given-names>A</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>L</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>F</given-names></name><name name-style="western"><surname>Elkifury</surname><given-names>J</given-names></name><name name-style="western"><surname>Gasparin</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanches</surname><given-names>P</given-names></name><name name-style="western"><surname>da Silva Junior</surname><given-names>DP</given-names></name><name name-style="western"><surname>Duss&#225;n-Sarria</surname><given-names>J</given-names></name><name name-style="western"><surname>Souza</surname><given-names>A</given-names></name><name name-style="western"><surname>da Silva Torres</surname><given-names>L</given-names></name><name name-style="western"><surname>Fregni</surname><given-names>F</given-names></name><name name-style="western"><surname>Caumo</surname><given-names>W</given-names></name></person-group>. <article-title>Potency of descending pain modulatory system is linked with peripheral sensory dysfunction in fibromyalgia: an exploratory study</article-title>. <source>Medicine (Baltimore)</source><year>2019</year>;<volume>98</volume>:<fpage>e13477</fpage>.<pub-id pub-id-type="pmid">30653087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000013477</pub-id><pub-id pub-id-type="pmcid">PMC6370006</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruun-Plesner</surname><given-names>K</given-names></name><name name-style="western"><surname>Blichfeldt-Eckhardt</surname><given-names>M</given-names></name><name name-style="western"><surname>Vaegter</surname><given-names>HB</given-names></name><name name-style="western"><surname>Lauridsen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Amris</surname><given-names>K</given-names></name><name name-style="western"><surname>Toft</surname><given-names>P</given-names></name></person-group>. <article-title>Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships</article-title>. <source>Pain Med</source><year>2020</year>;<volume>21</volume>:<fpage>2253</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">32068870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pm/pnaa001</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullingham</surname><given-names>RE</given-names></name><name name-style="western"><surname>McQuay</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Moore</surname><given-names>RA</given-names></name></person-group>. <article-title>Clinical pharmacokinetics of narcotic agonist-antagonist drugs</article-title>. <source>Clin Pharmacokinet</source><year>1983</year>;<volume>8</volume>:<fpage>332</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">6352139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-198308040-00004</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clauw</surname><given-names>D</given-names></name></person-group>. <article-title>Fibromyalgia: a clinical review</article-title>. <source>JAMA</source><year>2014</year>;<volume>311</volume>:<fpage>1547</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">24737367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2014.3266</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dirks</surname><given-names>J</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>K</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>J</given-names></name></person-group>. <article-title>The heat/capsaicin sensitization model: a methodologic study</article-title>. <source>J Pain</source><year>2003</year>;<volume>4</volume>:<fpage>122</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">14622709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1054/jpai.2003.10</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>R</given-names></name><name name-style="western"><surname>Dworkin</surname><given-names>R</given-names></name><name name-style="western"><surname>Turk</surname><given-names>D</given-names></name><name name-style="western"><surname>Angst</surname><given-names>MS</given-names></name><name name-style="western"><surname>Dionne</surname><given-names>R</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>R</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>P</given-names></name><name name-style="western"><surname>Haroutounian</surname><given-names>S</given-names></name><name name-style="western"><surname>Arendt-Nielsen</surname><given-names>L</given-names></name><name name-style="western"><surname>Attal</surname><given-names>N</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R</given-names></name><name name-style="western"><surname>Brell</surname><given-names>J</given-names></name><name name-style="western"><surname>Bujanover</surname><given-names>S</given-names></name><name name-style="western"><surname>Burke</surname><given-names>LB</given-names></name><name name-style="western"><surname>Carr</surname><given-names>D</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>AS</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>P</given-names></name><name name-style="western"><surname>Etropolski</surname><given-names>M</given-names></name><name name-style="western"><surname>Fillingim</surname><given-names>RB</given-names></name><name name-style="western"><surname>Gewandter</surname><given-names>JS</given-names></name><name name-style="western"><surname>Katz</surname><given-names>NP</given-names></name><name name-style="western"><surname>Kopecky</surname><given-names>EA</given-names></name><name name-style="western"><surname>Markman</surname><given-names>JD</given-names></name><name name-style="western"><surname>Nomikos</surname><given-names>G</given-names></name><name name-style="western"><surname>Porter</surname><given-names>L</given-names></name><name name-style="western"><surname>Rappaport</surname><given-names>BA</given-names></name><name name-style="western"><surname>Rice</surname><given-names>ASC</given-names></name><name name-style="western"><surname>Scavone</surname><given-names>JM</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>J</given-names></name><name name-style="western"><surname>Simon</surname><given-names>LS</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SM</given-names></name><name name-style="western"><surname>Tobias</surname><given-names>J</given-names></name><name name-style="western"><surname>Tockarshewsky</surname><given-names>T</given-names></name><name name-style="western"><surname>Veasley</surname><given-names>C</given-names></name><name name-style="western"><surname>Versavel</surname><given-names>M</given-names></name><name name-style="western"><surname>Wasan</surname><given-names>AD</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W</given-names></name><name name-style="western"><surname>Yarnitsky</surname><given-names>D</given-names></name></person-group>. <article-title>Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations</article-title>. <source>PAIN</source><year>2016</year>;<volume>157</volume>:<fpage>1851</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">27152687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000000602</pub-id><pub-id pub-id-type="pmcid">PMC5965275</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzcharles</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ste-Marie</surname><given-names>PA</given-names></name><name name-style="western"><surname>Gamsa</surname><given-names>A</given-names></name><name name-style="western"><surname>Ware</surname><given-names>MA</given-names></name><name name-style="western"><surname>Shir</surname><given-names>Y</given-names></name></person-group>. <article-title>Opioid use, misuse, and abuse in patients labeled as fibromyalgia</article-title>. <source>Am J Med</source><year>2011</year>;<volume>124</volume>:<fpage>955</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">21962316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2011.05.031</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freynhagen</surname><given-names>R</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R</given-names></name><name name-style="western"><surname>Gockel</surname><given-names>U</given-names></name><name name-style="western"><surname>Tolle</surname><given-names>T</given-names></name></person-group>. <article-title>painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain</article-title>. <source>Curr Med Res Opin</source><year>2006</year>;<volume>22</volume>:<fpage>1911</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">17022849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1185/030079906X132488</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenland</surname><given-names>S</given-names></name><name name-style="western"><surname>Senn</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Rothman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Carlin</surname><given-names>JB</given-names></name><name name-style="western"><surname>Poole</surname><given-names>C</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>SN</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group>. <article-title>Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations</article-title>. <source>Eur J Epidemiol</source><year>2016</year>;<volume>31</volume>:<fpage>337</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">27209009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-016-0149-3</pub-id><pub-id pub-id-type="pmcid">PMC4877414</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gylvin</surname><given-names>S</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>C</given-names></name><name name-style="western"><surname>Fink-Jensen</surname><given-names>A</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>P</given-names></name><name name-style="western"><surname>Kehlet</surname><given-names>H</given-names></name></person-group>. <article-title>Psychopharmacologic treatment and blood transfusion in fast-track total hip and knee arthroplasty</article-title>. <source>Transfusion</source><year>2017</year>;<volume>57</volume>:<fpage>971</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">28145024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/trf.13992</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatfield</surname><given-names>E</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>K</given-names></name><name name-style="western"><surname>Swidan</surname><given-names>S</given-names></name><name name-style="western"><surname>Ashman</surname><given-names>L</given-names></name></person-group>. <article-title>Use of low-dose naltrexone in the management of chronic pain conditions: a systematic review</article-title>. <source>J Am Dental Assoc</source><year>2020</year>;<volume>151</volume>:<fpage>891</fpage>&#8211;<lpage>902.e1</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.adaj.2020.08.019</pub-id><pub-id pub-id-type="pmid">33228882</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbert</surname><given-names>R</given-names></name></person-group>. <article-title>Research note: significance testing and hypothesis testing: meaningless, misleading and mostly unnecessary</article-title>. <source>J Physiother</source><year>2019</year>;<volume>65</volume>:<fpage>178</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">31175039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jphys.2019.05.001</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="webpage"><article-title>International Association for the Study of Pain</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://iasp-pain.org/resources/terminology/" ext-link-type="uri">iasp-pain.org/resources/terminology/</ext-link>. Accessed May 2021.</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>D</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang-James</surname><given-names>Y</given-names></name><name name-style="western"><surname>Faraone</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B</given-names></name></person-group>. <article-title>The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia</article-title>. <source>Front Psychiatry</source><year>2021</year>;<volume>12</volume>:<fpage>593842</fpage>.<pub-id pub-id-type="pmid">33664680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.593842</pub-id><pub-id pub-id-type="pmcid">PMC7921161</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosek</surname><given-names>E</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>GF</given-names></name><name name-style="western"><surname>Mico</surname><given-names>JA</given-names></name><name name-style="western"><surname>Rice</surname><given-names>ASC</given-names></name><name name-style="western"><surname>Rief</surname><given-names>W</given-names></name><name name-style="western"><surname>Sluka</surname><given-names>AK</given-names></name></person-group>. <article-title>Do we need a third mechanistic descriptor for chronic pain states?</article-title><source>PAIN</source><year>2016</year>;<volume>7</volume>:<fpage>1382</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000000507</pub-id><pub-id pub-id-type="pmid">26835783</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leal</surname><given-names>B</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>J</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>C</given-names></name><name name-style="western"><surname>Rangel</surname><given-names>R</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A</given-names></name><name name-style="western"><surname>Bettencourt</surname><given-names>A</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramalheira</surname><given-names>J</given-names></name><name name-style="western"><surname>Silva</surname><given-names>BM</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>AM</given-names></name><name name-style="western"><surname>Costa</surname><given-names>PP</given-names></name></person-group>. <article-title>Brain expression of inflammatory mediators in mesial temporal lobe epilepsy patients</article-title>. <source>J Neuroimmunol</source><year>2017</year>;<volume>313</volume>:<fpage>82</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">29153613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2017.10.014</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macfarlane</surname><given-names>G</given-names></name><name name-style="western"><surname>Kronisch</surname><given-names>C</given-names></name><name name-style="western"><surname>Dean</surname><given-names>L</given-names></name><name name-style="western"><surname>Atzeni</surname><given-names>F</given-names></name><name name-style="western"><surname>H&#228;user</surname><given-names>W</given-names></name><name name-style="western"><surname>Fluss</surname><given-names>E</given-names></name><name name-style="western"><surname>Choy</surname><given-names>E</given-names></name><name name-style="western"><surname>Kosek E Amris</surname><given-names>K</given-names></name><name name-style="western"><surname>Branco</surname><given-names>J</given-names></name><name name-style="western"><surname>Dincer</surname><given-names>F</given-names></name><name name-style="western"><surname>Leino-Arjas</surname><given-names>P</given-names></name><name name-style="western"><surname>Longley</surname><given-names>K</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>GM</given-names></name><name name-style="western"><surname>Makri</surname><given-names>S</given-names></name><name name-style="western"><surname>Perrot</surname><given-names>S</given-names></name><name name-style="western"><surname>Sarzi-Puttini</surname><given-names>P</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>A</given-names></name><name name-style="western"><surname>Jones</surname><given-names>G</given-names></name></person-group>. <article-title>EULAR revised recommendations for the management of fibromyalgia</article-title>. <source>Ann Rheum Dis</source><year>2017</year>;<volume>76</volume>:<fpage>318</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">27377815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2016-209724</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melzack</surname><given-names>R</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J</given-names></name></person-group>. <article-title>Pain</article-title>. <source>Wiley Interdiscip Rev Cogn Sci</source><year>2013</year>;<volume>4</volume>:<fpage>1</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">26304172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wcs.1201</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molero</surname><given-names>Y</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>H</given-names></name><name name-style="western"><surname>D'Onofrio</surname><given-names>BM</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Fazel</surname><given-names>S</given-names></name></person-group>. <article-title>Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden</article-title>. <source>BMJ</source><year>2019</year>;<volume>365</volume>:<fpage>2147</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.l2147</pub-id><pub-id pub-id-type="pmcid">PMC6559335</pub-id><pub-id pub-id-type="pmid">31189556</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;cke</surname><given-names>M</given-names></name><name name-style="western"><surname>Cuhls</surname><given-names>H</given-names></name><name name-style="western"><surname>Radbruch</surname><given-names>L</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R</given-names></name><name name-style="western"><surname>Maier</surname><given-names>C</given-names></name><name name-style="western"><surname>T&#246;lle</surname><given-names>T</given-names></name><name name-style="western"><surname>Treede</surname><given-names>R-D</given-names></name><name name-style="western"><surname>Rolke</surname><given-names>R</given-names></name></person-group>. <article-title>Quantitative sensory testing (QST). English version</article-title>. <source>Schmerz</source><year>2021</year>;<volume>35</volume>:<fpage>153</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26826097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00482-015-0093-2</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oaks</surname><given-names>Z</given-names></name><name name-style="western"><surname>Stage</surname><given-names>A</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>B</given-names></name><name name-style="western"><surname>Faraone</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B</given-names></name></person-group>. <article-title>Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone</article-title>. <source>Discov Med</source><year>2018</year>;<volume>26</volume>:<fpage>197</fpage>&#8211;<lpage>206</lpage>.<pub-id pub-id-type="pmid">30695679</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostling</surname><given-names>PS</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>KS</given-names></name><name name-style="western"><surname>Anyama</surname><given-names>B</given-names></name><name name-style="western"><surname>Helander</surname><given-names>EM</given-names></name><name name-style="western"><surname>Wyche</surname><given-names>MQ</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>AD</given-names></name></person-group>. <article-title>America's opioid epidemic: a comprehensive review and look into the rising crisis</article-title>. <source>Curr Pain Headache Rep</source><year>2018</year>;<volume>22</volume>:<fpage>32</fpage>.<pub-id pub-id-type="pmid">29619569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11916-018-0685-5</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkitny</surname><given-names>L</given-names></name><name name-style="western"><surname>Younger</surname><given-names>J</given-names></name></person-group>. <article-title>Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia</article-title>. <source>Biomedicines</source><year>2017</year>;<volume>5</volume>:<fpage>16</fpage>.<pub-id pub-id-type="pmid">28536359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines5020016</pub-id><pub-id pub-id-type="pmcid">PMC5489802</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patten</surname><given-names>DK</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>BG</given-names></name><name name-style="western"><surname>Berlau</surname><given-names>DJ</given-names></name></person-group>. <article-title>The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders</article-title>. <source>Pharmacotherapy</source><year>2018</year>;<volume>38</volume>:<fpage>382</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29377216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.2086</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>A</given-names></name><name name-style="western"><surname>Gitlin</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gross</surname><given-names>RA</given-names></name><name name-style="western"><surname>Posner</surname><given-names>K</given-names></name><name name-style="western"><surname>Dworkin</surname><given-names>RH</given-names></name></person-group>. <article-title>Suicidality associated with antiepileptic drugs: implications for the treatment of neuropathic pain and fibromyalgia</article-title>. <source>PAIN</source><year>2013</year>:<fpage>3345</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2012.12.024</pub-id><pub-id pub-id-type="pmcid">PMC4556238</pub-id><pub-id pub-id-type="pmid">23375513</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>K</given-names></name><name name-style="western"><surname>Rowbotham</surname><given-names>M</given-names></name></person-group>. <article-title>A new human experimental pain model: the heat/capsaicin sensitization model</article-title>. <source>Neuroreport</source><year>1999</year>;<volume>10</volume>:<fpage>1511</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">10380972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001756-199905140-00022</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quartana</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>CM</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>RR</given-names></name></person-group>. <article-title>Pain catastrophizing: a critical review</article-title>. <source>Expert Rev Neurother</source><year>2009</year>;<volume>9</volume>:<fpage>745</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">19402782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/ERN.09.34</pub-id><pub-id pub-id-type="pmcid">PMC2696024</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raknes</surname><given-names>G</given-names></name><name name-style="western"><surname>Sm&#229;brekke</surname><given-names>L</given-names></name></person-group>. <article-title>A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study</article-title>. <source>Pharmacoepidemiol Drug Saf</source><year>2017</year>;<volume>26</volume>:<fpage>136</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">27670755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.4110</pub-id><pub-id pub-id-type="pmcid">PMC5298009</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raknes</surname><given-names>G</given-names></name><name name-style="western"><surname>Sm&#229;brekke</surname><given-names>L</given-names></name></person-group>. <article-title>Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database</article-title>. <source>Pharmacoepidemiol Drug Saf</source><year>2017</year>;<volume>26</volume>:<fpage>685</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">28370746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.4201</pub-id><pub-id pub-id-type="pmcid">PMC5485080</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringsted</surname><given-names>T</given-names></name><name name-style="western"><surname>Enghuus</surname><given-names>C</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>M</given-names></name><name name-style="western"><surname>Werner</surname><given-names>MU</given-names></name></person-group>. <article-title>Demarcation of secondary hyperalgesia zones: punctate stimulation pressure matters</article-title>. <source>J Neurosci Methods</source><year>2015</year>;<volume>256</volume>:<fpage>74</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">26310180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneumeth.2015.08.018</pub-id><pub-id pub-id-type="pmcid">PMC4651781</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>JP</given-names></name><name name-style="western"><surname>Stock</surname><given-names>H</given-names></name><name name-style="western"><surname>Bingaman</surname><given-names>S</given-names></name><name name-style="western"><surname>Mauger</surname><given-names>D</given-names></name><name name-style="western"><surname>Rogosnitzky</surname><given-names>M</given-names></name><name name-style="western"><surname>Zagon</surname><given-names>IS</given-names></name></person-group>. <article-title>Low-dose naltrexone therapy improves active Crohn's disease</article-title>. <source>Am J Gastroenterol</source><year>2007</year>;<volume>102</volume>:<fpage>820</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17222320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1572-0241.2007.01045.x</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stannard</surname><given-names>C</given-names></name></person-group>. <article-title>Tramadol is not &#8220;opioid-lite&#8221;</article-title>. <source>BMJ</source><year>2019</year>;<volume>356</volume>:<fpage>I2095</fpage>.</mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudakin</surname><given-names>D</given-names></name></person-group>. <article-title>Naltrexone: not just for opioids anymore</article-title>. <source>J Med Toxicol</source><year>2016</year>;<volume>12</volume>:<fpage>71</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">26546222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13181-015-0512-x</pub-id><pub-id pub-id-type="pmcid">PMC4781804</pub-id></mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>M</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>B</given-names></name><name name-style="western"><surname>Haythornthwaite</surname><given-names>J</given-names></name><name name-style="western"><surname>Keefe</surname><given-names>F</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>L</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>J</given-names></name></person-group>. <article-title>Theoretical perspectives on the relation between catastrophizing and pain</article-title>. <source>Clin J Pain</source><year>2001</year>;<volume>17</volume>:<fpage>52</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">11289089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00002508-200103000-00008</pub-id></mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talotta</surname><given-names>R</given-names></name><name name-style="western"><surname>Bazzichi</surname><given-names>L</given-names></name><name name-style="western"><surname>Di Franco</surname><given-names>M</given-names></name><name name-style="western"><surname>Casale</surname><given-names>R</given-names></name><name name-style="western"><surname>Batticciotto</surname><given-names>A</given-names></name><name name-style="western"><surname>Gerardi</surname><given-names>MC</given-names></name><name name-style="western"><surname>Sarzi-Puttini</surname><given-names>P</given-names></name></person-group>. <article-title>One year in review 2017: fibromyalgia</article-title>. <source>Clin Exp Rheumatol</source><year>2017</year>;<volume>35</volume>(<issue>suppl 105</issue>):<fpage>6</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">28681712</pub-id></mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thybo</surname><given-names>K</given-names></name><name name-style="western"><surname>Hagi-Pedersen</surname><given-names>D</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>J</given-names></name><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><name name-style="western"><surname>Nersesjan</surname><given-names>M</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>N</given-names></name><name name-style="western"><surname>Overgaard</surname><given-names>S</given-names></name><name name-style="western"><surname>Schr&#248;der</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H</given-names></name><name name-style="western"><surname>Bj&#248;rck</surname><given-names>J</given-names></name><name name-style="western"><surname>Skovmand</surname><given-names>K</given-names></name><name name-style="western"><surname>Buus-Nielsen</surname><given-names>M</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>C</given-names></name><name name-style="western"><surname>Kruuse</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindholm</surname><given-names>P</given-names></name><name name-style="western"><surname>Mathiesen</surname><given-names>O</given-names></name></person-group>. <article-title>Effect of combination of paracetamol (acetaminophen) and ibuprofen vs either alone on patient-controlled morphine consumption in the first 24 hours after total hip arthroplasty: the PANSAID randomized clinical trial</article-title>. <source>JAMA</source><year>2019</year>;<volume>6</volume>:<fpage>562</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.22039</pub-id><pub-id pub-id-type="pmcid">PMC6439592</pub-id><pub-id pub-id-type="pmid">30747964</pub-id></mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toljan</surname><given-names>K</given-names></name><name name-style="western"><surname>Vrooman</surname><given-names>B</given-names></name></person-group>. <article-title>Low-dose naltrexone (LDN)&#8212;review of therapeutic utilization</article-title>. <source>Med Sci</source><year>2018</year>;<volume>6</volume>:<fpage>82</fpage>&#8211;<lpage>100</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/medsci6040082</pub-id><pub-id pub-id-type="pmcid">PMC6313374</pub-id><pub-id pub-id-type="pmid">30248938</pub-id></mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turk</surname><given-names>D</given-names></name><name name-style="western"><surname>Adams</surname><given-names>L</given-names></name></person-group>. <article-title>Using a biopsychosocial perspective in the treatment of fibromyalgia patients</article-title>. <source>Pain Manag</source><year>2016</year>;<volume>6</volume>:<fpage>357</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">27301637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/pmt-2016-0003</pub-id></mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vadivelu</surname><given-names>N</given-names></name><name name-style="western"><surname>Kai</surname><given-names>A</given-names></name><name name-style="western"><surname>Kodumudi</surname><given-names>V</given-names></name><name name-style="western"><surname>Sramcik</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>AD</given-names></name></person-group>. <article-title>The opioid crisis: a comprehensive overview</article-title>. <source>Curr Pain Headache Rep</source><year>2018</year>;<volume>22</volume>:<fpage>16</fpage>.<pub-id pub-id-type="pmid">29476358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11916-018-0670-z</pub-id></mixed-citation></ref><ref id="R48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vernon</surname><given-names>M</given-names></name><name name-style="western"><surname>Brandenburg</surname><given-names>N</given-names></name><name name-style="western"><surname>Alvir</surname><given-names>JMJ</given-names></name><name name-style="western"><surname>Griesing</surname><given-names>T</given-names></name><name name-style="western"><surname>Revicki</surname><given-names>D</given-names></name></person-group>. <article-title>Reliability, validity, and responsiveness of the daily sleep interference scale among diabetic peripheral neuropathy and postherpetic neuralgia patients</article-title>. <source>J Pain Symptom Manag</source><year>2008</year>;<volume>36</volume>:<fpage>54</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2007.09.016</pub-id><pub-id pub-id-type="pmid">18411009</pub-id></mixed-citation></ref><ref id="R49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wasserstein</surname><given-names>LN</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>NA</given-names></name></person-group>. <article-title>The ASA statement on p-values: context, process, and purpose</article-title>. <source>Am Statist</source><year>2016</year>;<volume>2</volume>:<fpage>129</fpage>&#8211;<lpage>33</lpage>.</mixed-citation></ref><ref id="R50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wasserstein</surname><given-names>RL</given-names></name><name name-style="western"><surname>Schirm</surname><given-names>AL</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>NA</given-names></name></person-group>. <article-title>Moving to a world beyond &#8220;p &lt; 0.05&#8221;</article-title>. <source>Am Statist</source><year>2019</year>;<volume>73</volume>:<fpage>1</fpage>&#8211;<lpage>19</lpage>.</mixed-citation></ref><ref id="R51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>D</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>L</given-names></name></person-group>. <article-title>Measures of fibromyalgia: fibromyalgia impact questionnaire (FIQ), brief pain inventory (BPI), multidimensional fatigue inventory (MFI-20), medical outcomes study (MOS) sleep scale, and multiple ability self-report questionnaire (MASQ)</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2011</year>;<volume>63</volume>:<fpage>86</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.20531</pub-id><pub-id pub-id-type="pmcid">PMC3527080</pub-id><pub-id pub-id-type="pmid">22588773</pub-id></mixed-citation></ref><ref id="R52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfe</surname><given-names>F</given-names></name><name name-style="western"><surname>Smythe</surname><given-names>HA</given-names></name><name name-style="western"><surname>Yunus</surname><given-names>MB</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>RM</given-names></name><name name-style="western"><surname>Bombardier</surname><given-names>C</given-names></name><name name-style="western"><surname>Goldenberg</surname><given-names>DL</given-names></name><name name-style="western"><surname>Tugwell</surname><given-names>P</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>SM</given-names></name><name name-style="western"><surname>Abeles</surname><given-names>M</given-names></name><name name-style="western"><surname>Clark</surname><given-names>P</given-names></name><name name-style="western"><surname>Fam</surname><given-names>AG</given-names></name><name name-style="western"><surname>Farber</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Fiechtner</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Michael Franklin</surname><given-names>C</given-names></name><name name-style="western"><surname>Gatter</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hamaty</surname><given-names>D</given-names></name><name name-style="western"><surname>Lessard</surname><given-names>J</given-names></name><name name-style="western"><surname>Lichtbroun</surname><given-names>AS</given-names></name><name name-style="western"><surname>Masi</surname><given-names>AT</given-names></name><name name-style="western"><surname>Mccain</surname><given-names>GA</given-names></name><name name-style="western"><surname>John Reynolds</surname><given-names>W</given-names></name><name name-style="western"><surname>Romano</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Jon Russell</surname><given-names>I</given-names></name><name name-style="western"><surname>Sheon</surname><given-names>RP</given-names></name></person-group>. <article-title>The American College of Rheumatology 1990 criteria for the classification of fibromyalgia</article-title>. <source>Arthritis Rheum</source><year>1990</year>;<volume>33</volume>:<fpage>160</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">2306288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.1780330203</pub-id></mixed-citation></ref><ref id="R53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfe</surname><given-names>F</given-names></name><name name-style="western"><surname>Clauw</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Fitzcharles</surname><given-names>MA</given-names></name><name name-style="western"><surname>Goldenberg</surname><given-names>DL</given-names></name><name name-style="western"><surname>H&#228;user</surname><given-names>W</given-names></name><name name-style="western"><surname>Katz</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mease</surname><given-names>P</given-names></name><name name-style="western"><surname>Russell</surname><given-names>AS</given-names></name><name name-style="western"><surname>Russell</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Winfield</surname><given-names>JB</given-names></name></person-group>. <article-title>Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia</article-title>. <source>J Rheumatol</source><year>2011</year>;<volume>38</volume>:<fpage>1113</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">21285161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3899/jrheum.100594</pub-id></mixed-citation></ref><ref id="R54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfe</surname><given-names>F</given-names></name><name name-style="western"><surname>Clauw</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Fitzcharles</surname><given-names>MA</given-names></name><name name-style="western"><surname>Goldenberg</surname><given-names>DL</given-names></name><name name-style="western"><surname>H&#228;user</surname><given-names>W</given-names></name><name name-style="western"><surname>Katz</surname><given-names>RL</given-names></name><name name-style="western"><surname>Mease</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Russell</surname><given-names>A</given-names></name><name name-style="western"><surname>Russell</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Walitt</surname><given-names>B</given-names></name></person-group>. <article-title>2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria</article-title>. <source>Semin Arthritis Rheum</source><year>2016</year>;<volume>46</volume>:<fpage>319</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">27916278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semarthrit.2016.08.012</pub-id></mixed-citation></ref><ref id="R55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younger</surname><given-names>J</given-names></name><name name-style="western"><surname>Zautra</surname><given-names>A</given-names></name><name name-style="western"><surname>Cummins</surname><given-names>E</given-names></name></person-group>. <article-title>Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology</article-title>. <source>PLoS One</source><year>2009</year>;<volume>4</volume>:<fpage>e5180</fpage>.<pub-id pub-id-type="pmid">19365548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0005180</pub-id><pub-id pub-id-type="pmcid">PMC2664472</pub-id></mixed-citation></ref><ref id="R56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younger</surname><given-names>J</given-names></name><name name-style="western"><surname>Noor</surname><given-names>N</given-names></name><name name-style="western"><surname>McCue</surname><given-names>R</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>S</given-names></name></person-group>. <article-title>Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels</article-title>. <source>Arthritis Rheum</source><year>2013</year>;<volume>65</volume>:<fpage>529</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">23359310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.37734</pub-id></mixed-citation></ref><ref id="R57"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younger</surname><given-names>J</given-names></name><name name-style="western"><surname>Parkitny</surname><given-names>L</given-names></name><name name-style="western"><surname>McLain</surname><given-names>D</given-names></name></person-group>. <article-title>The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain</article-title>. <source>Clin Rheumatol</source><year>2014</year>;<volume>33</volume>:<fpage>451</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24526250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10067-014-2517-2</pub-id><pub-id pub-id-type="pmcid">PMC3962576</pub-id></mixed-citation></ref><ref id="R58"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zigmond</surname><given-names>A</given-names></name><name name-style="western"><surname>Snaith</surname><given-names>R</given-names></name></person-group>. <article-title>The hospital anxiety and depression scale</article-title>. <source>Acta Psychiatr Scand</source><year>1983</year>;<volume>67</volume>:<fpage>361</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">6880820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0447.1983.tb09716.x</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>